News | Breast Imaging | November 28, 2021

Lunit announces FDA 510(k) clearance for Lunit INSIGHT MMG, now available for clinical use in U.S. hospitals and medical institutions

AI can detect breast cancer at an earlier stage; accuracy proven via studies published in major journals like JAMA Oncology and Lancet Digital Health

Lunit also holds FDA clearance for its chest X-ray triage AI solution, all to be introduced during RSNA 2021, booth #4545


Lunit, a leading medical AI provider, announced that the U.S. Food and Drug Administration (FDA) 510(k) has cleared its AI solution for breast cancer detection, Lunit INSIGHT MMG. Along with its chest X-ray triaging solution, Lunit INSIGHT CXR Triage, the company’s AI solution for both chest X-ray and mammography is now commercially available across the U.S.

“I am delighted to deliver the great news and to introduce Lunit INSIGHT MMG to healthcare professionals and institutions across the US,” said Brandon Suh, CEO of Lunit. “With our AI solution, we hope to increase the efficiency and accuracy of mammography screening as well as chest x-ray triaging. We can assist radiologists diagnose diseases at an earlier stage, helping patients be treated at the right time.”

Lunit INSIGHT MMG is one of the company’s most mature radiology products which analyzes mammography images with high accuracy. It provides the location of lesions suspicious of breast cancer and an abnormality score that reflects the AI’s confidence of the existence of detected lesions.

The product is trained with a large-scale data of more than 240,000 mammography cases that include up to 50,000 breast cancer cases and is known to show excellent performance in finding breast cancer at an earlier stage.

According to a study published in JAMA Oncology in 2020, Lunit INSIGHT MMG showed the best accuracy among three commercialized AI to identify breast cancer. It was found to have around 15% higher sensitivity compared to the other two algorithms. The FDA-cleared AI solution has been previously CE marked and approved for commercial sales in more than 35 countries worldwide.

“This is a huge milestone and business opportunity for us, as the U.S. is one of the largest and most important markets that covers more than 45% of the global breast imaging market,” added Suh. “Based on the FDA clearance, we will not only bring diagnostic value to medical professionals and patients in the U.S. but leverage our business to be a leading global provider of breast AI solution.”

Lunit INSIGHT MMG will be showcased at RSNA 2021, AI Showcase - booth #4545, Nov. 28 – Dec. 2, 2021, in Chicago.

For more information: https://www.lunit.io/en


Related Content

News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 13, 2025 — Covera Health recently announced that Advanced Radiology Services (ARS) has joined its national Quality ...

Time November 17, 2025
arrow
News | Radiology Imaging

Nov. 13, 2025 — Medical imaging AI company Avicenna.AI has launched AVI, a new platform that delivers AI results ...

Time November 13, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Artificial Intelligence

Nov. 6 — 2025, Gradient Health and DataFirst have announced a strategic partnership designed to bridge the gap between ...

Time November 12, 2025
arrow
News | RSNA 2025

Nov. 7, 2025 — Coreline Soft will introduce its chest AI platform AVIEW 2.0 at RSNA 2025 (Nov. 30 – Dec. 4, Chicago) ...

Time November 10, 2025
arrow
News | Teleradiology

Nov. 4, 2025 — Virtual Radiologic (vRad) recently announced the successful commercialization of The vRad Platform — a ...

Time November 10, 2025
arrow
News | Lung Imaging

Nov. 3, 2025 — RevealDx, a leader in the characterization of lung nodules, has introduced MDR Certification of RevealAI ...

Time November 07, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
Feature | Teleradiology | Kyle Hardner

Once viewed as a solution for after-hours coverage, teleradiology is rapidly expanding into a critical part of radiology ...

Time November 06, 2025
arrow
Subscribe Now